AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03353753
Drug: DCC-2618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral KIT/PDGFRA kinase inhibitor
Trial: NCT03353753
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00990158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A daily dose of matching placebo medication given orally for a total of 7 months
Trial: NCT02704494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 capsule daily
Trial: NCT04626193
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
Trial: NCT03441893
Drug: Placebo tabletes
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab. Placebo (shugar pills) will be given to the participants
Trial: NCT01546896
Drug: buspirone+alprazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg
Trial: NCT00218426
Drug: placebo implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo implant resembles active medication
Trial: NCT03286712
Drug: Renogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
Trial: NCT03953092
Drug: YG1699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YG1699 at Multiple Doses
Trial: NCT03953092
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos
Trial: NCT02353039
Drug: GC6101A 37.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 12.5mg of GC6101A t.i.d for 2 weeks.
Trial: NCT02353039
Drug: GC6101A 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 25mg of GC6101A t.i.d for 2 weeks.
Trial: NCT02353039
Drug: GC6101A 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 50mg of GC6101A t.i.d for 2 weeks.
Trial: NCT02353039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer placebo t.i.d for 2 weeks
Trial: NCT00089453
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
Trial: NCT01603069
Drug: AZD3241 300 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
Trial: NCT01603069
Drug: AZD3241 600 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
Trial: NCT01603069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to AZD3241 BID
Trial: NCT01358968
Drug: LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a 1-hour infusion.
Trial: NCT01358968
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03033823
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
Trial: NCT03593655
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing 200 mg FTC/300 mg TDF
Trial: NCT01362218
Drug: Simvastatin, ramipril, acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
Trial: NCT02271126
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulation provided to patients in ECMO
Trial: NCT00688636
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
Trial: NCT00566267
Drug: simvastatin 20 mg/ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see protocol
Trial: NCT01518712
Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Trial: NCT01518712
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Trial: NCT01478568
Drug: desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02586233
Drug: DS-1040b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
Trial: NCT02586233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
Trial: NCT01690169
Drug: NNC0113-0987
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
Trial: NCT01690169
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of oral placebo administered.
Trial: NCT04379219
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: giving methotrexate at least 1 w week before surgery
Trial: NCT00193219
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 350 mg IV
Trial: NCT02462941
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testing escalating doses of adenosine in pediatric heart transplant patients
Trial: NCT00996021
Drug: GSK1349572 250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an experimental HIV medication in the integrase inhibitor class.
Trial: NCT00996021
Drug: Placebo Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a liquid with no drug in it.
Trial: NCT01418053
Drug: caraway oil
RxNorm normalized name: Caraway Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
Trial: NCT00934427
Drug: vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
Trial: NCT03424824
Drug: BP1.3656 low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily oral administration at the low dose
Trial: NCT03424824
Drug: BP1.3656 intermediate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily oral administration at the intermediate dose
Trial: NCT03424824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily oral administration
Trial: NCT03424824
Drug: BP1.3656 high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily oral administration at the high dose
Trial: NCT02952924
Drug: RO7049389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049389 will be administered as per schedule described in individual arm.
Trial: NCT02158299
Drug: Avitene
RxNorm normalized name: Avitene
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02567214
Drug: Ultibro®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
Trial: NCT02567214
Drug: Spiriva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
Trial: NCT00091312
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00091312
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01122030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets or solution for oral administration
Trial: NCT00091312
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01581281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
Trial: NCT00544011
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00544011
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02094053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (oral) once daily, for 24 weeks
Trial: NCT00501046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9g /day (3 times a day)
Trial: NCT00501046
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9g /day (3 times a day)
Trial: NCT00139685
Drug: Depo-Provera Contraceptive Injection - DP150CI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01266434
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg once daily for 8 weeks
Trial: NCT01567618
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
Trial: NCT03580876
Drug: addition of azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: impact of addition of azathioprine after a switch of a second anti-TNF agent
Trial: NCT03580876
Drug: Switch to a second anti-TNF drug alone
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to a second anti-TNF drug alone without addition of azathioprine
Trial: NCT00698789
Drug: INCB019602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of INCB019602 in AM with placebo administration in PM
Trial: NCT00698789
Drug: INCB019602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg in PM with placebo administration in AM
Trial: NCT00698789
Drug: INCB019602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg in PM with placebo administration in AM
Trial: NCT00698789
Drug: INCB019602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
Trial: NCT00698789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration in AM or PM depending on treatment arm dosing regimen.
Trial: NCT03342638
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Potent immunosuppressive agent; an alkylating agent
Trial: NCT00450086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g per day
Trial: NCT01666691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
Trial: NCT02581111
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182141
Drug: BIBF 1120 ES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01507168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv Days 1 and 8, and every 2 weeks thereafter
Trial: NCT04403698
Drug: Alendronate Effervescent Oral Tablet
RxNorm normalized name: alendronate Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
Trial: NCT01844830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients supplied in identical nasal sprayer
Trial: NCT02300220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule, twice daily for 1 week
Trial: NCT02035982
Drug: Cholinesterase Inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency.
Trial: NCT02035982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
Trial: NCT03336619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice daily for five days
Trial: NCT01446458
Drug: Modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
Trial: NCT00240552
Drug: Telzir®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02634931
Drug: NPC-12G gel
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-12G gel is administered topically twice a day for 52 weeks or longer
Trial: NCT00168025
Drug: Immunoglobulins Intravenous (Human)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04591795
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium, 25 mg enteric-coated tablets
Trial: NCT00605410
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT00618449
Drug: Azithromcyin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
Trial: NCT00618449
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
Trial: NCT04741334
Drug: direct anticoagulant
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure to direct anticoagulant
Trial: NCT04741334
Drug: Dicumarols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure to dicumarols
Trial: NCT04474119
Drug: KN046 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks.
Trial: NCT02235987
Drug: DG3173
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
Trial: NCT00438399
Drug: C. propionate - Corticosteroid 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application
Trial: NCT00438399
Drug: C. propionate- Corticosteroid 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application
Trial: NCT00438399
Drug: Corticosteroid 1- C. propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application
Trial: NCT00438399
Drug: Corticosteroid 2 - C. propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application
Trial: NCT00438399
Drug: Corticosteroid 3 - C. propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application
Trial: NCT00479557
Drug: Placebo: Phosphate buffered saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
Trial: NCT02235948
Drug: folic acid supplementation
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.8mg folic acid/day
Trial: NCT01973452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04504370
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
Trial: NCT04504370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Trial: NCT03052842
Drug: C16G2 Strip
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial Peptide
Trial: NCT02176291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT00118729
Drug: GW685698X Aqueous Nasal Spray
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01858610
Drug: Irbeasartan/hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03041909
Drug: GBT440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug
Trial: NCT02089620
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a daily placebo similar in size and structure to calvar.
Trial: NCT02089620
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
Trial: NCT02603185
Drug: Hemay007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02603185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no